Recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma NCT05256225 Conditions Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, +17 more Locations University of Alabama at Birmingham Cancer Center — Birmingham, Alabama, United States Alaska Women's Cancer Care — Anchorage, Alaska, United States Banner University Medical Center - Tucson — Tucson, Arizona, United States University of Arizona Cancer Center-North Campus — Tucson, Arizona, United States View all 409 locations View more locations Show fewer locations Loading locations... View Trial Details
